Large Outflow of Money Witnessed in Baxter International

Baxter International (BAX) : The total negative money flow of $2.53 million on Wednesday indicates selling on strength. The inflow of money on upticks was $13.12 million, compared to $15.64 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.84. The negative money flow of $1.98 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $1.98 million. The price action in the Baxter International (BAX) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $47.41 with a gain of $0.08 , a change of 0.17% over the previous days close. The stock registered -0.17% for the week.


Baxter International Inc. is up 7.21% in the last 3-month period. Year-to-Date the stock performance stands at 26.7%.

Baxter International (BAX) has an average broker rating of 2.78, which is interpreted as a Hold, as rated by 12 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 9 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Baxter International (NYSE:BAX): The stock opened at $47.39 and touched an intraday high of $47.94 on Wednesday. During the day, the stock corrected to an intraday low of $47.16, however, the bulls stepped in and pushed the price higher to close in the green at $47.92 with a gain of 1.25% for the day. The total traded volume for the day was 3,489,139. The stock had closed at $47.33 in the previous trading session.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.